Choosing between dual and three-drug antiretroviral therapy in aging and comorbid people with HIV: a narrative review - Takeaways - MDSpire

Choosing between dual and three-drug antiretroviral therapy in aging and comorbid people with HIV: a narrative review

  • By

  • Maria Vittoria Cossu

  • Maddalena Matone

  • Valentina Iannone

  • Chiara Fusetti

  • Valeria Colombo

  • Andrea Gori

  • Anna Lisa Ridolfo

  • Cristina Gervasoni

  • June 22, 2026

  • 0 min

Share

  • 1

    Combination antiretroviral therapy has transformed HIV into a chronic condition, improving life expectancy for people with HIV.

  • 2

    The demographic profile of people with HIV has shifted, with a growing proportion aged 50 years and older in high-income countries.

  • 3

    Older people with HIV often face multimorbidity, requiring a treatment approach that balances efficacy, toxicity, and patient preferences.

  • 4

    Dual antiretroviral therapy (2DR) is emerging as a clinically relevant alternative to three-drug regimens (3DR) for older patients.

  • 5

    Current guidelines endorse specific 2DR strategies based on randomized trials showing non-inferior efficacy compared to 3DR.

Original Source(s)

Choosing between dual and three-drug antiretroviral therapy in aging and comorbid people with HIV: a narrative review

  • by Maria Vittoria Cossu, Maddalena Matone, Valentina Iannone, Chiara Fusetti, Valeria Colombo, Andrea Gori, Anna Lisa Ridolfo, Cristina Gervasoni

  • June 22, 2026

Related Content

Immunoglobulin G N-glycosylation predicts outcome in sepsis caused by pathogenic Gram-negative bacteria and Gram-positive bacteria: a nested case-control study

cGAS-STING pathway in innate immunity and its cell-specific role in kidney diseases

Immunity: defense against infections essential for all living organisms